Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Sage fails first of 4 tests for key prospect, exits Parkinson's
Sage Therapeutics has set a bad PRECEDENT for dalzanemdor with a phase 2 failure in Parkinson's disease.
Nick Paul Taylor
Apr 17, 2024 8:34am
Gritstone ground down by phase 2 cancer vaccine fail
Apr 2, 2024 5:09am
Ampio prepares to wind down after final therapeutic dream dies
Mar 26, 2024 9:01am
Innate drops monotherapy plans for lacutamab in type of lymphoma
Mar 21, 2024 8:27am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
Mar 14, 2024 8:27am